. This technique has high staff acceptance which aIlows large numbers to benefit and reduces the cost almost to the level quoted for aspirin. Theatre technicians or nurses fit the gaiters on all anaesthetized patients unless specificaIly requested not to do so. Protection is still given, therefore, to night emergencies, cases under junior or locum staff, and those in whom major resuscitative problems may distract the anaesthetist and surgeon from the more mundane chore of preventing a remote complication. In Eastbourne, approximately 300 intermediate and major cases per month receive routine prophylaxis using this method. Battery charges amount to 3.5p per patient plus 12p for equipment and repairs and each year about £550 is spent to protect 3600 patients. According to Davies and Salzman, treatment of this large number with, say, low-dose heparin would cost £54 000 even if each month we could persuade 300 patients and their nurses that the extra work and complications were worthwhile. Yours faithfuIly J M POWLEY 6 April 1981
Copies of these letters were sent to Mr Davies, whose reply foIlows: Dear Sir, Thank you for giving me the opportunity to reply to the comments of Messrs Negus and Powley. The following represent my own views on the points raised.
Negus and colleagues, in their preliminary report of experience with ultra-low dose heparin, conclude that larger series are now required to establish the place of this new approach to heparin prophylaxis (Negus et al. 1980 ). The results of such studies are awaited with interest. Numerous pharmacological methods of prophylaxis are now available and, indeed, in use (Morris 1980) but experience with some of them is, as yet, too restricted to allow satisfactory comparisons to be made with more traditional techniques. Salzman and I chose to consider only the more commonly employed prophylactic regimens when constructing our cost benefit analysis whilst acknowledging that the recommendations of such an analysis must be provisional and subject to future revision in the light of future well-designed clinical trials (Salzman & Davies 1980) . We felt that there were insufficient data available on many agents for consideration in a meaningful analysis.
